Loading…
Based on limited available metadata, the FDA issued a warning letter to Intrathecal Compounding Specialist, LLC on September 15, 2020, regarding violations related to drug compounding operations. While the specific violations are not detailed in the metadata provided, the warning letter was issued under FDA's drug regulatory authority. Without access to the full warning letter text, the precise nature of the compliance issues cannot be determined, but they likely relate to compounding pharmacy practices, quality standards, or manufacturing controls for intrathecal drug preparations.